Locations:
Search IconSearch
July 14, 2017/Cancer

Well-Differentiated Lipomatous Tumors: A Case Series (Video)

Soft tissue pathology service’s most common consult

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never looks for lipoblasts when examining a well-differentiated fatty tumor.

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

Advertisement

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never bothers to identify lipoblasts when examining a well-differentiated fatty tumor.

In the final case, he examines a large retroperitoneal mass from an elderly patient and highlights the importance of examining the slide’s periphery in order to identify any well-differentiated liposarcomatous components. Find out why Dr. Goldblum argues that the type of spindle cell sarcoma is inconsequential in this case in the video below:

Pathology Insights: Well-Differentiated Lipomatous Tumors with John Goldblum, MD

The accurate diagnosis, grading and staging of benign and malignant soft tissue neoplasms, as well as mesenchymal neoplasms of the skin and parenchymal organs, can be challenging. Cleveland Clinic’s soft tissue pathology service, led by Karen Fritchie, MD, offers consultations on some of the most difficult cases in soft tissue pathology as well as a fellowship program and continuing medical education opportunities for practicing pathologists.

Advertisement

Related Articles

Dr. Khorana
April 25, 2025/Cancer/News & Insight
Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Ad